Holm G, Johansson S, Vedin A, Wilhelmsson C, Smith U
Acta Med Scand. 1980;208(3):187-91. doi: 10.1111/j.0954-6820.1980.tb01175.x.
Blood glucose and plasma insulin levels were studied in ten adult diabetics treated in a cross-over fashion for at least three weeks with alprenolol, a non-selective beta-blocker, or with metoprolol, a cardioselective beta 1-blocker. Dietary intake was controlled three days prior to the study which comprised both i.v. and oral glucose tolerance tests. Mean fasting blood glucose levels were significantly higher on alprenolol than on metoprolol. The increase in fasting blood glucose was particularly pronounced in two patients. In these subjects the glucose tolerance following both an i.v. and an oral glucose load was reduced when treatment was switched from metoprolol to alprenolol. Lower plasma insulin levels in response to glucose were also found in these patients on alprenolol than on metoprolol. The mean insulin levels for all ten patients did not differ significantly between the two treatment periods. These data show that treatment with a non-selective beta-blocker can in some patients cause a considerable deterioration of the glucose tolerance, presumably due to inhibition of insulin release.
对十名成年糖尿病患者进行了研究,这些患者采用交叉方式,分别接受非选择性β受体阻滞剂阿普洛尔或心脏选择性β1受体阻滞剂美托洛尔治疗至少三周。在研究前三天控制饮食摄入,研究包括静脉注射和口服葡萄糖耐量试验。服用阿普洛尔时的平均空腹血糖水平显著高于服用美托洛尔时。两名患者空腹血糖升高尤为明显。在这些受试者中,当治疗从美托洛尔换为阿普洛尔时,静脉注射和口服葡萄糖负荷后的葡萄糖耐量均降低。服用阿普洛尔的这些患者对葡萄糖的血浆胰岛素反应水平也低于服用美托洛尔时。十名患者在两个治疗阶段的平均胰岛素水平无显著差异。这些数据表明,非选择性β受体阻滞剂治疗在某些患者中可能导致葡萄糖耐量显著恶化,可能是由于抑制了胰岛素释放。